In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae-Reference-Cited by-同舟云学术

In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ishikawa Kazuhiro¹²,Uehara Yuki²³⁴⁵,Mori Nobuyoshi²,Mikami Yumiko³,Tokioka Sayuri⁶,Kobayashi Daiki⁷,Goke Hisa¹,Inukai Tatsuya¹,Sakurai Aki⁸⁹,Doi Yohei⁸⁹¹⁰,Kawakami Sayoko¹¹,Kayama Shizuo¹¹,Sugai Motoyuki¹¹^ORCID,Nakamura Shigeki¹^ORCID

Affiliation:

1. Department of Microbiology, Tokyo Medical University, Tokyo, Japan

2. Department of Infectious Diseases, St. Luke’s International Hospital, Tokyo, Japan

3. Department of Clinical Laboratory, St. Luke’s International Hospital, Tokyo, Japan

4. Department of Microbiology, Juntendo University Faculty of Medicine, Tokyo, Japan

5. Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan

6. Department of Cardiovascular Medicine, Sendai Medical Center, Sendai, Japan

7. St. Luke’s International University Graduate School of Public Health, Tokyo, Japan

8. Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

9. Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

10. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

11. Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan

Abstract

Faropenem (FRPM) is active against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales , but evidence for its efficacy is lacking. This study determined the correlation between the susceptibility by disk diffusion method and the MIC of FRPM for third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae , and the effectiveness of FRPM for the treatment of urinary tract infection (UTI) caused by these two bacteria in a retrospective cohort analysis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00125-22

Reference19 articles.

1. The structure of β-lactamases

2. Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality

3. A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients

4. Japan Nosocomial Infections Surveillance. 2020. JANIS annual open report (all facilities) Japan nosocomial infections surveillance. Japan Ministry of Health Labor and Welfare Tokyo Japan. https://janis.mhlw.go.jp/english/report/index.html.

5. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections;Journal of Infection and Chemotherapy;2024-07